SG Americas Securities LLC Sells 90,015 Shares of IQVIA Holdings Inc. $IQV

SG Americas Securities LLC lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 78.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,045 shares of the medical research company’s stock after selling 90,015 shares during the period. SG Americas Securities LLC’s holdings in IQVIA were worth $4,567,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs purchased a new stake in shares of IQVIA during the first quarter valued at $1,384,000. Investors Research Corp increased its holdings in IQVIA by 19,772.7% in the 2nd quarter. Investors Research Corp now owns 2,186 shares of the medical research company’s stock worth $344,000 after buying an additional 2,175 shares in the last quarter. Finally, Everpar Advisors LLC raised its position in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

NYSE:IQV opened at $242.70 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a 50-day simple moving average of $224.37 and a two-hundred day simple moving average of $200.77. The firm has a market capitalization of $41.33 billion, a PE ratio of 33.29, a P/E/G ratio of 2.47 and a beta of 1.36. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.05.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on IQV. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. HSBC raised IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Finally, TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and raised their target price for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $249.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.